We specialize in supporting client decisions in clinical trials and drug development in the field of immunology. Through our vast collection of research and model components, we can apply pre-built model components to your project, build novel models, or license our technology for your model development and prediction needs. All of our modeling projects center around developing the highest predictive power in the least amount of time, while meeting/exceeding client specifications.
|
Disease Models |
Key Outputs |
Supported Therapeutics |
|
Rheumatoid Arthritis
|
Swollen/tender joint counts (SJC/TJC) ACR20/50/70/90 DAS28(3)-CRP/ESR Low disease activity Remission Serum cytokines and biomarkers Serum cell counts |
MTX 5-ASA Corticosteroids JAK inhibitors Anti-TNFs Anti-IL6s Anti-IL17s Anti-T and B cell therapies Anti-Survival therapies Anti-Migration therapies |
|
Psoriatic Arthritis / Psoriasis |
Swollen/tender joint counts ACR20/50/70 DAS28(3)-CRP/ESR PASI 50/75/90/100 Serum cytokines and biomarkers Serum cell counts |
MTX 5-ASA Corticosteroids JAK inhibitors Anti-TNFs Anti-IL6s Anti-IL17s Anti-IL12/23 Anti-T and B cell therapies Anti-Survival therapies Anti-Migration therapies |
|
Ulcerative Colitis |
Mayo score Response/Remission Mucosal healing Serum cytokines and biomarkers |
MTX 5-ASA Corticosteroids Anti-TNFs JAK inhibitors S1P receptor antagonist |
| Acute Myeloid Leukemia (AML) |
Best Overall Response (BOR) based on bone marrow and blood blast counts:
Response vs Non-response Minimal Residual Disease (MRD = < 0.1% Blasts) Death Duration of Response (DoR) Relapse Disease-specific Biomarkers:
|
Hypomethylating Agents (i.e. azacytidine) Chemotherapies (cytarabine) BCL-2 inhibitor (venetoclax) Monoclonal antibodies (e.g. anti-CD47) |
| Multiple Myeloma (MM) |
Best Overall Response (BOR) based on M-protein changes:
Overall Response Rate (ORR) Time To Response (TTR) Duration of Response (DoR) Disease-specific Biomarkers:
|
Immunomodulatory Drugs (IMiDs) Antibody-Drug Conjugates (ADCs) Immune Cell Engagers (NK and T cell Engagers) Monoclonal Antibodies (e.g. Daratumumab) Chimeric Antigen Receptor T cell Therapies (CAR T therapies) Steroids (i.e. Dexamethasone) |
| Melanoma* |
Tumor Size Best Overall Response (BOR) |
Client Proprietary |
| Non-small cell lung cancer (NSCLC)* |
Percent change in Tumor Diameter Best Overall Response (BOR) Progressive Disease (PD) Stable Disease (SD) Responders (RR) |
Monoclonal Antibodies
Chemotherapies
|
| Diffuse large B cell lymphoma (DLBCL)* |
Complete Responder (CR) Partial Responder (PR) Tumor Cell Number |
Chimeric Antigen Receptor T cell Therapies (CAR T therapies)
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) Immunomodulatory Drugs (IMiDs)
|
|
Sepsis Multi-Organ Dysfunction
|
Mean arterial pressure (MAP) Central venous pressure (CVP) Blood oxygen saturation (O2sat) Breathing frequency Tidal volume Blood gases (PaO2, PaCO2) Creatinine Urinary output (UOP) Coagulation proteins |
Fluid therapy Vasopressors Ventilators Diuretics Dialysis Antibiotics |
|
Trauma |
Cytokines Immune cells Coagulation proteins Blood loss Mean arterial pressure (MAP) Blood oxygen saturation (O2sat) |
Fluid therapies Blood products Ventilators |
* Indicates models developed internally OR for a specific purpose. These models are currently limited in functionality compared to our platform models.